DOCSLIB.ORG

Today's Drugs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Today's Drugs 22 August 1970 Patients from the Tropics-Rowland BRiTISH 449 What has been said regarding persons working overseas Conclusions but whose long-standing home is the United Kingdom applies Clearly the greatest hurdle to overcome is to discover that Br Med J: first published as 10.1136/bmj.3.5720.449 on 22 August 1970. Downloaded from to this third group of patients. Rapid air travel enables such the patient has been overseas, information which is not persons to reach this country during the incubation period of always volunteered. Acute illness should be managed as some serious infective disorders of which typhoid fever, outlined in this article and failure to make a diagnosis calls smallpox, and malaria are the most common, and many of for early assistance from one of the specialized hospitals. Less the patients seen suffering from these disorders have recently acute illness should be investigated as for permanent resi- left their country of origin. dents of this country, but failure to make a satisfactory diag- Acute illness should be managed as for group 1 patients; in nosis should suggest an expert opinion, again early rather those suffering less acute illness it is probably advisable to than late; this might be sought more often by general hospi- obtain further opinion either from a general hospital or from tals as well as by general practitioners. one specializing in tropical disorders. It is understandable that general hospitals should like to keep an "interesting Tropical Diseases Hospitals patient," though this is not always in the best interest of the Hospital for Tropical Diseases, 4 St. Pancras Way, London individual; they too might do better by obtaining expert N.W.1. Department of Tropical Medicine, Liverpool School of Tropical opinion and by obtaining it early rather than as a last resort Medicine, Pembroke Place, Liverpool 3. when all other investigations have proved negative. As there Tropical Diseases Unit, Eastern General Hospital, Edinburgh 6. are good and bad ways of handling an acute abdomen, a spontaneous pneumothorax, and a placenta praevia so there REFERENCES are good and bad ways of handling an amoebic liver abscess Maegraith, B. G., Transactions of the Royal Society of Tropical Medicine and Hygiene, 1969, 63, 689. or an infection with P. falciparum. Shute, P. G., and Maryon, M., British Medical Journal, 1969, 2, 781. TODAY'S DRUGS With the help of expert contributors we print in this section dose levels in gout, small doses (1-2 g. daily) lessening uric notes on drugs in common use. acid output and causing elevation of serum uric acid levels, larger dosage (5-6 g.) having the opposite effect. It should Non-steroid Anti-inflammatory Agents be said in passing that aspirin has little part to play in the treatment of acute gout. In the 1920s and even In larger dosage aspirin has a definite anti-inflammatory later it was fashionable to treat fevers and for with analgesic-antipyretic substances. As there were then no effect, this reason it is usually the first choice in the effective bactericidal or bacteriostatic agents all treatment of rheumatoid arthritis. Soluble aspirin is generally one could do http://www.bmj.com/ was to attempt to reduce pain, fever, and other unpleasant the most popular, but all preparations may cause gastro- symptoms. Today, in spite of a vast selection of antibiotics, intestinal complications and bleeding. Popular proprietary many inflammatory diseases cannot be rapidly cured but can preparations are Paynocil (glycinated aspirin), each tablet be symptomatically relieved; examples are virus pneumonias, containing 0.6 g. which dissolves on the tongue, Palaprin forte connective tissue disorders such as rheumatoid arthritis, rheu- (aloxiprin) each tablet containing 0.6 g. which may be matic fever and systemic lupus erythematosus, glandular fever, chewed, sucked, swallowed, or dispersed in water, Bufferin sarcoidosis, and gout. (aspirin buffered with magnesium carbonate and aluminium Patients with such disorders are often glycinate), enteric glad of symptomatic relief. Since the anti-inflammatory agents coated preparations, and several others. have also analgesic and This anti-inflammatory analgesic action has been shown by on 30 September 2021 by guest. Protected copyright. antipyretic properties they are Lim2 to be at extremely useful in this widely scattered group of inflamma- least in part peripheral. Unfortunately, the high tory disorders. dosage necessary to achieve the effect is often poorly Anti-inflammatory agents available are: tolerated, and dosage has to be reduced or the drug changed the salicylates- to something better tolerated. At high dose particularly aspirin in all its different forms; the levels compound pyrazolones-phenylbutazone and oxyphenbutazone; indo- preparaticns containing phenacetin, caffeine, or codeine are methacin; the anthranilates-mefenamic and flufenamic never used. acids; and ibuprofen. Though gold salts, chloroquine, and immunosuppressive agents- can be legitimately considered to be anti-inflammatory Pyrazolones long-term agents, they are not discussed here. Phenylbutazone and its metabolite oxyphenbutazone are effective long-acting, slowly metabolized, anti-inflammatory, Salicylates antipyretic, analgesic agents. They are only slowly broken down and are excreted in the urine largely as a number of Aspirin in its various forms is usually first choice in the water-soluble metabolites. They are firmly bound to plasma treatment of any inflammatory disorder, whether it be a com- protein, largely to albumin and alpha globulin, and for this mon cold, rheumatoid arthritis, or glandular fever. Sodium reason they exert an even, prolonged action, which is particu- salicylate has been largely given up in favour of aspirin as larly effective in the chronic arthropathies and in acute gout the latter drug relieves symptoms more effectively. Aspirin is (total daily dosage being 200-400 mg. in the former and rapidly absorbed from stomach and small intestine and begins 600 mg. in the latter condition). When treating acute gout the to ease pain within 15 minutes of ingestion. Used in low dos- dosage should be gradually reduced by 100 mg. daily as the age it is essentially an analgesic agent only; in larger dosage, attack comes under control. Though oedema, rashes, and such as 5 g. or more daily, it has a measurable anti-inflam- gastrointestinal complications are known to occur, the much matory effect also, as has been shown in patients with rheuma- rarer, though more dangerous, toxic effects are toid arthritis.' Similarly, it has different effects at different haematological-neutropenia, thrombocytopenia, or aplastic 450 22 August 1970 Non-steroid Anti-inflammatory Agents MEDICALBRITISHJOURNAL anaemia.3 For this reason blood counts should be done every est side effect is a dose-related one, an unpleasant swimmy or few weeks if the patient is on regular therapy, and immedi- muzzy sensation in the head or a true headache, sometimes Br Med J: first published as 10.1136/bmj.3.5720.449 on 22 August 1970. Downloaded from ately if suggestive symptoms arise, such as buccal ulceration, severe.10 unexplained pyrexia, sore throats, stomatitis, or odd ill feel- As with tinnitus in patients on salicylates and nausea with ings which cannot be accurately described. Buccal ulceration digitalis, this toxic effect is met by reduction of dosage. Dys- commonly occurs, however, without any changes in the blood pepsia, on the other hand, sometimes with gastrointestinal and is in most cases of nuisance value only. bleeding, is not dose related1' and may occur at any stage of Its even therapeutic action makes phenylbutazone particu- therapy on almost any dosage. Prepyloric ulceration may larly effective in disorders such as ankylosing spondylitis, occur'2 which radiologically may closely resemble a malignant where frequent aches and pains and constant stiffness is the condition; but such ulcers diminish and disappear, usually rule throughout the 24 hours, but the pyrazolones are also within four weeks of stopping the drug. useful in the treatment of osteoarthritis, rheumatoid arthritis, Indomethacin is available in 25 mg. capsules taken by Reiter's (Brodie's) disease, and a number of other rheumatic mouth with or after food, as an elixir 25 mg. per 5 ml. and in afflictions. In non-arthritic conditions, such as thrombo- suppository form (100 mg.). In many rheumatic disorders phlebitis, where pain and swelling play a part in the more pain is experienced at night and in the early morning disease the pyrazolones may also prove useful, and in non- than in the day, and painful morning stiffness is characteristic inflammatory conditions of bone such as metastatic malignant of rheumatoid arthritis, ankylosing spondylitis, some cases of and Paget's disease symptoms may be at least partly relieved periarthritis of the shoulder, and a number of other condi- in some cases. Both phenylbutazone and oxyphenbutazone tions. A 100 mg. suppository inserted late at night or three to may be given in suppository form (250 mg.) and the former four capsules (75-100 mg.) by mouth taken with food on retir- by intramuscular injections (600 mg.), but the oral route ing may help the patient through the night very effectively," usually proves the most satisfactory. Nifenazone has not the larger dose being tolerated since headaches rarely waken proved to be as effective as its predecessors.' the patient from sleep. The usual total daily dosage is two, A few more rare side effects may be noted. Thyroid three, or four capsules (50-100 mg.) taken with food. There is enlargement may very rarely occur, with clinical features of great individual variation in tolerance, some patients hypothyroidism, owing to blocking of iodine uptake by the experiencing headaches on 50 mg., others none on 200 mg. a thyroid gland. Enlargement of the salivary glands with day. Rashes are rare, purpura rarer still. Buccal ulceration dryness of the mouth may be erroneously thought to be due may sometimes occur, but in almost all cases without any to Sj6gren's syndrome rather than to the drug.
Load more

Recommended publications
  • Metabolic-Hydroxy and Carboxy Functionalization of Alkyl Moieties in Drug Molecules: Prediction of Structure Influence and Pharmacologic Activity
    molecules Review Metabolic-Hydroxy and Carboxy Functionalization of Alkyl Moieties in Drug Molecules: Prediction of Structure Influence and Pharmacologic Activity Babiker M. El-Haj 1,* and Samrein B.M. Ahmed 2 1 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, University of Science and Technology of Fujairah, Fufairah 00971, UAE 2 College of Medicine, Sharjah Institute for Medical Research, University of Sharjah, Sharjah 00971, UAE; [email protected] * Correspondence: [email protected] Received: 6 February 2020; Accepted: 7 April 2020; Published: 22 April 2020 Abstract: Alkyl moieties—open chain or cyclic, linear, or branched—are common in drug molecules. The hydrophobicity of alkyl moieties in drug molecules is modified by metabolic hydroxy functionalization via free-radical intermediates to give primary, secondary, or tertiary alcohols depending on the class of the substrate carbon. The hydroxymethyl groups resulting from the functionalization of methyl groups are mostly oxidized further to carboxyl groups to give carboxy metabolites. As observed from the surveyed cases in this review, hydroxy functionalization leads to loss, attenuation, or retention of pharmacologic activity with respect to the parent drug. On the other hand, carboxy functionalization leads to a loss of activity with the exception of only a few cases in which activity is retained. The exceptions are those groups in which the carboxy functionalization occurs at a position distant from a well-defined primary pharmacophore. Some hydroxy metabolites, which are equiactive with their parent drugs, have been developed into ester prodrugs while carboxy metabolites, which are equiactive to their parent drugs, have been developed into drugs as per se.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub
    US 2010O221245A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub. Date: Sep. 2, 2010 (54) TOPICAL SKIN CARE COMPOSITION Publication Classification (51) Int. Cl. (76) Inventor: Audrey Kunin, Mission Hills, KS A 6LX 39/395 (2006.01) (US) A6II 3L/235 (2006.01) A638/16 (2006.01) Correspondence Address: (52) U.S. Cl. ......................... 424/133.1: 514/533: 514/12 HUSCH BLACKWELL SANDERS LLP (57) ABSTRACT 4801 Main Street, Suite 1000 - KANSAS CITY, MO 64112 (US) The present invention is directed to a topical skin care com position. The composition has the unique ability to treat acne without drying out the user's skin. In particular, the compo (21) Appl. No.: 12/395,251 sition includes a base, an antibacterial agent, at least one anti-inflammatory agent, and at least one antioxidant. The (22) Filed: Feb. 27, 2009 antibacterial agent may be benzoyl peroxide. US 2010/0221 245 A1 Sep. 2, 2010 TOPCAL SKIN CARE COMPOSITION stay of acne treatment since the 1950s. Skin irritation is the most common side effect of benzoyl peroxide and other anti BACKGROUND OF THE INVENTION biotic usage. Some treatments can be severe and can leave the 0001. The present invention generally relates to composi user's skin excessively dry. Excessive use of some acne prod tions and methods for producing topical skin care. Acne Vul ucts may cause redness, dryness of the face, and can actually garis, or acne, is a common skin disease that is prevalent in lead to more acne. Therefore, it would be beneficial to provide teenagers and young adults.
    [Show full text]
  • Characterising the Risk of Major Bleeding in Patients With
    EU PE&PV Research Network under the Framework Service Contract (nr. EMA/2015/27/PH) Study Protocol Characterising the risk of major bleeding in patients with Non-Valvular Atrial Fibrillation: non-interventional study of patients taking Direct Oral Anticoagulants in the EU Version 3.0 1 June 2018 EU PAS Register No: 16014 EMA/2015/27/PH EUPAS16014 Version 3.0 1 June 2018 1 TABLE OF CONTENTS 1 Title ........................................................................................................................................... 5 2 Marketing authorization holder ................................................................................................. 5 3 Responsible parties ................................................................................................................... 5 4 Abstract ..................................................................................................................................... 6 5 Amendments and updates ......................................................................................................... 7 6 Milestones ................................................................................................................................. 8 7 Rationale and background ......................................................................................................... 9 8 Research question and objectives .............................................................................................. 9 9 Research methods ....................................................................................................................
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Choice of Drugs in the Treatment of Rheumatoid Arthritis
    RHEUMATOLOGY IN GENERAL PRACTICE 7 Those with predominant but never exclusive involvement of the terminal finger joint, usually associated with changes in the nail of the same finger; they are serologically negative. There may be a swollen finger with loss of the skin markings-a sort of dactylitis, again serologically negative. (2) Those with a much more severe process which produces loss of movement in the spine and changes in the sacroiliac joints much the same as those in ankylosing spondylitis; unlike ankylosing spondylitis, it produces severe deformity often with ankylosis in peripheral joints. Many of the finger joints become deformed and ankylosed. (3) Those cases indistinguishable from rheumatoid arthritis although the majority are sero-negative. The Stevens Johnson syndrome produces acute effusions, particularly in large joints. It is sometimes associated with the rash of erythema multiforme, always with ulceration in the mouth and genital tract; the mouth ulcers are accompanied by sloughing, unlike those of Beh9et's syndrome which we come to next. BehCet's syndrome, originally described as a combination of orogenital ulceration with relapsing iritis, is now expanded to include skin lesions, other eye lesions, lesions of the central nervous system, thrombophlebitis migrans, and arthropathy (occurring in 64 per cent). The onset is acute, often affecting only a single joint and settling without residual trouble. Choice of drugs in the treatment of rheumatoid arthritis Dr Dudley Hart, M.D., F.R.C.P. (Consultant physician, Westminster Hospital and Medical School) There are many potential drugs for the treatment of rheumatoid disease, but what are we treating in this disorder? Pain in rheumatoid arthritis is but one of the symp- toms.
    [Show full text]
  • Sulfonylureas
    Therapeutic Class Overview Sulfonylureas INTRODUCTION In the United States (US), diabetes mellitus affects more than 30 million people and is the 7th leading cause of death (Centers for Disease Control and Prevention [CDC] 2018). Type 2 diabetes mellitus (T2DM) is the most common form of diabetes and is characterized by elevated fasting and postprandial glucose concentrations (American Diabetes Association [ADA] 2019[a]). It is a chronic illness that requires continuing medical care and ongoing patient self-management education and support to prevent acute complications and to reduce the risk of long-term complications (ADA 2019[b]). ○ Complications of T2DM include hypertension, heart disease, stroke, vision loss, nephropathy, and neuropathy (ADA 2019[a]). In addition to dietary and lifestyle management, T2DM can be treated with insulin, one or more oral medications, or a combination of both. Many patients with T2DM will require combination therapy (Garber et al 2019). Classes of oral medications for the management of blood glucose levels in patients with T2DM focus on increasing insulin secretion, increasing insulin responsiveness, or both, decreasing the rate of carbohydrate absorption, decreasing the rate of hepatic glucose production, decreasing the rate of glucagon secretion, and blocking glucose reabsorption by the kidney (Garber et al 2019). Pharmacologic options for T2DM include sulfonylureas (SFUs), biguanides, thiazolidinediones (TZDs), meglitinides, alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogs, amylinomimetics, sodium-glucose cotransporter 2 (SGLT2) inhibitors, combination products, and insulin (Garber et al 2019). SFUs are the oldest of the oral antidiabetic medications, and all agents are available generically. The SFUs can be divided into 2 categories: first-generation and second-generation.
    [Show full text]
  • 18 Analgesics Anti-Inflammatory Drugs and Antipyretics the Dosage of Alfentanil Used Depends on Whether the 2
    18 Analgesics Anti-inflammatory Drugs and Antipyretics The dosage of alfentanil used depends on whether the 2. Virkkilä M, et al. Pharmacokinetics and effects of i.m. alfentanil minutes). However, some considered that there was no over- patient has spontaneous respiration or assisted ventila- as premedication for day-case ophthalmic surgery in elderly pa- all advantage of epidural over intravenous alfentanil either as tients. Br J Anaesth 1993; 71: 507–11. patient-controlled analgesia2 or by continuous infusion.3 tion and on the expected duration of anaesthesia. Doses 3. Hughes DA, Hill DA. Intrathecal alfentanil with and without bupivacaine for analgesia in labour. Anaesthesia 2000; 55: 1. Chrubasik J, et al. Relative analgesic potency of epidural fenta- are adjusted according to the needs of the patient. Chil- 1116–21. nyl, alfentanil, and morphine in treatment of postoperative pain. dren may require higher or more frequent doses than Anesthesiology 1988; 68: 929–33. Administration in children. Alfentanil is licensed in the UK 2. Chauvin M, et al. Equivalence of postoperative analgesia with adults, whereas the elderly or debilitated patients may for use in ventilated children during surgical procedures as an patient-controlled intravenous or epidural alfentanil. Anesth An- require lower or less frequent doses. Obese patients analgesic and adjunct to general anaesthetics or as a primary an- alg 1993; 76: 1251–8. may require doses based on their ideal (lean) body- aesthetic. When used as an adjunct in the maintenance of gen- 3. van den Nieuwenhuyzen MCO, et al. Epidural vs intravenous infusion of alfentanil in the management of postoperative pain weight.
    [Show full text]
  • Bleeding Disorders of Importance in Dental Care and Related Patient Management
    Clinical P RACTIC E Bleeding Disorders of Importance in Dental Care and Related Patient Management Contact Author Anurag Gupta, BDS; Joel B. Epstein, DMD, MSD, FRCD(C); Robert J. Cabay, MD, DDS Dr. Epstein Email: [email protected] ABSTRACT Oral care providers must be aware of the impact of bleeding disorders on the manage- ment of dental patients. Initial recognition of a bleeding disorder, which may indicate the presence of a systemic pathologic process, may occur in dental practice. Furthermore, prophylactic, restorative and surgical dental care of patients with bleeding disorders is best accomplished by practitioners who are knowledgeable about the pathology, com- plications and treatment options associated with these conditions. The purpose of this paper is to review common bleeding disorders and their effects on the delivery of oral health care. For citation purposes, the electronic version MeSH Key Words: blood coagulation/physiology blood coagulation disorders/complications dental care is the definitive version of this article: www.cda-adc.ca/jcda/vol-73/issue-1/77.html entists must be aware of the impact of The patient should be asked for any history bleeding disorders on the management of significant and prolonged bleeding after Dof their patients. Proper dental and med- dental extraction or bleeding from gingivae. ical evaluation of patients is therefore neces- A history of nasal or oral bleeding should sary before treatment, especially if an invasive be noted. Many bleeding disorders, such as dental procedure is planned. Patient evalua- hemophilia and von Willebrand’s disease, tion and history should begin with standard run in families; therefore, a family history medical questionnaires.
    [Show full text]
  • (Glyburide) Tablets USP 1.25, 2.5 and 5 Mg DESCRIPTION Diaßeta
    Diaßeta® (glyburide) Tablets USP 1.25, 2.5 and 5 mg DESCRIPTION Diaßeta® (glyburide) is an oral blood-glucose-lowering drug of the sulfonylurea class. It is a white, crystalline compound, formulated as tablets of 1.25 mg, 2.5 mg, and 5 mg strengths for oral administration. Diaßeta tablets USP contain the active ingredient glyburide and the following inactive ingredients: dibasic calcium phosphate USP, magnesium stearate NF, microcrystalline cellulose NF, sodium alginate NF, talc USP. Diaßeta 1.25 mg tablets USP also contain D&C Yellow #10 Aluminum Lake and FD&C Red #40 Aluminum Lake. Diaßeta 2.5 mg tablets USP also contain FD&C Red #40 Aluminum Lake. Diaßeta 5 mg tablets USP also contain D&C Yellow #10 Aluminum Lake, and FD&C Blue #1. Chemically, Diaßeta is identified as 1-[[p-[2-(5-Chloro-o-anisamido)ethyl]phenyl]sulfonyl]-3-cyclohexylurea. The CAS Registry Number is 10238-21-8. The structural formula is: Cl CONHCH2CH2 SO2NHCONH OCH3 The molecular weight is 493.99. The aqueous solubility of Diaßeta increases with pH as a result of salt formation. CLINICAL PHARMACOLOGY Diaßeta appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which Diaßeta lowers blood glucose during long-term administration has not been clearly established. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may play a part in the mechanism of action of oral sulfonylurea hypoglycemic drugs.
    [Show full text]
  • Study Protocol
    Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Synopsis Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects with Severe Sepsis and Coagulopathy Name of Sponsor/Company: Asahi Kasei Pharma America Corporation Name of Investigational Product: ART-123 Name of Active Ingredient: thrombomodulin alpha Objectives Primary: x To evaluate whether ART-123, when administered to subjects with bacterial infection complicated by at least one organ dysfunction and coagulopathy, can reduce mortality. x To evaluate the safety of ART-123 in this population. Secondary: x Assessment of the efficacy of ART-123 in resolution of organ dysfunction in this population. x Assessment of anti-drug antibody development in subjects with coagulopathy due to bacterial infection treated with ART-123. Study Center(s): Phase of Development: Global study, up to 350 study centers Phase 3 Study Period: Estimated time of first subject enrollment: 3Q 2012 Estimated time of last subject enrollment: 3Q 2018 Number of Subjects (planned): Approximately 800 randomized subjects. Page 2 of 116 Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Diagnosis and Main Criteria for Inclusion of Study Subjects: This study targets critically ill subjects with severe sepsis requiring the level of care that is normally associated with treatment in an intensive care unit (ICU) setting. The inclusion criteria for organ dysfunction and coagulopathy must be met within a 24 hour period. 1. Subjects must be receiving treatment in an ICU or in an acute care setting (e.g., Emergency Room, Recovery Room).
    [Show full text]
  • Structure Based Drug Designing for Diabetes Mellitus K
    Journal of Proteomics & Bioinformatics - Open Access Research Article OPEN ACCESS Freely available online doi:10.4172/jpb.1000157 JPB/Vol.3 Issue 11 Structure Based Drug Designing for Diabetes Mellitus K. Ramanathan1*, H. Karthick2 and N. Arun3 1Department of Bioinformatics, Thanthai Hans Roever College,Perambalur, India 2Department of Bioinformatics, PRIST University, Thanjavur, India 3Department of Biochemistry, Thanthai Hans Roever College, Perambalur, India Abstract In recent years much work has been invested in to developing computer algorithms to facilitate research in the field of molecular biology. A large focus has been on structure based drug designing. In this work we address a specific suitable ligand for diabetes mellitus. We have been retrieved that the Gene and Protein which is responsible for diabetes mellitus and target binding site has been identified. The list of drugs are retrieved which are used to treat diabetes mellitus and the best drug ligand has been identified based on molecular docking. We also described that the hydrophobic activity of the ligand. Finally we have observed that the ligand acetohexamide has the highest hydrophobic activity when compared with other drugs. These findings suggest the possible involvement of systematic mechanism of drug designing process. Keywords: Diabetes mellitus; Drug designing; Hydrophobic activity; complex knowledge of the preferred orientations in turn may be Molecular docking used to predict the binding strength of association or binding affinity between two molecules. Docking is frequently used to predict the Introduction binding orientations of small molecules drug candidates to protein Diabetes is a disease in which blood glucose levels are above targets in order to in turn predict the affinity and activity of the normal.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]